Invitae Corporation Stock News

NVTA earnings call for the period ending June 30, 2022.

Invitae Corp (NYSE:NVTA ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Hoki Luk - Head, IR Kenneth Knight - President, CEO & Director Roxi Wen - CFO Conference Call

Invitae (NVTA) delivered earnings and revenue surprises of 8.11% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) delivered earnings and revenue surprises of 8.11% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. TOP Financial Group Limited (NASDAQ: TOP) jumped 102.7% to settle at $20.57 after gain

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 0% and 11.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6

iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 15.96% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SAN FRANCISCO , Aug. 2, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August

An analyst downgrades his recommendation on the stock, making a brutal cut to his price target while doing so.

An analyst downgrades his recommendation on the stock, making a brutal cut to his price target while doing so.

1Life Healthcare, Inc. (ONEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Upgrades For Agile Therapeutics Inc (NASDAQ:AGRX), Maxim Group upgraded the previous rating of Hold to Buy. For the first quarter, Agile Therapeutics had an EPS of $3.78, compared to year-ago quarter

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.